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 Abbreviation list 
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2 
COVID-19: coronavirus disease 2019  
CLD: chronic lung disease 
M, IQR: Median (Inter Quartile Range) 
Max, IQR: Max (Inter Quartile Range) 
NPPV: noninvasive positive-pressure ventilation 
HFNC: high-flow nasal cannula (HFNC) oxygen therapy 
NPS: nasopharyngeal swab 
SP: sputum specimen 
HR (95%CI): hazard ratio (95% confidence interval). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Abstract 
Background 
The viral shedding duration of SARS-CoV-2 has not been fully defined. Consecutive 
detection of SARS-CoV-2 RNA from respiratory tract specimens is essential for 
determining duration of virus shedding and providing evidence to optimize the 
clinical management of COVID-19.  
Research Question 
What are the shedding durations of SARS-CoV-2 RNA in upper and lower respiratory 
tract specimens respectively? What are their associated risk factors? 
Study Design and Methods 
A total of 68 patients with COVID-19 admitted to Wuhan Taikang Tongji Hospital 
and Huoshenshan Hospital from February 10, 2020 to March 20, 2020 were recruited. 
Consecutive SARS-CoV-2 RNA detection from paired specimens of nasopharyngeal 
swab (NPS) and sputum were carried out. The clinical characteristics of patients were 
recorded for further analysis.  
Results 
SARS-CoV-2 RNA was detected from NPS in 48 (70.6%) patients, and from sputum 
specimens in 30 (44.1%) patients. The median duration of viral shedding from sputum 
specimens (34 days, IQR 24-40 days) was significantly longer than from NPS (19 
days, IQR 14-25 days; P<0.001). Elderly age was an independent factor associated 
with prolonged virus shedding time of SARS-CoV-2 (HR 1.71, 1.01-2.93). It was 
noteworthy that in 9 patients the viral RNA was detected in sputum after NPS turned 
negative. Chronic lung disease and steroids were associated with virus detection in 
sputum, and diabetes mellitus was associated with virus detection in both NPS and 
sputum.  
Interpretation 
These findings may impact a test based clearance discharge criteria given patients 
with COVID-19 may shed virus longer in their lower respiratory tracts, with potential 
implication for prolonged transmission risk. In addition, more attention should be 
given to elderly patients who might have prolonged viral shedding duration.
Introduction 
Since December 2019, an outbreak of pneumonia started in Wuhan, China and 
gradually spread around world. The pathogen has been identified as a novel 
enveloped RNA beta-coronavirus named severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), which has a phylogenetic similarity to SARS-CoV, and 
has now been designated coronavirus disease 2019 (COVID-19) by the WHO1. The 
clinical manifestations of COVID-19 vary diversely from asymptomatic infection to 
mild upper respiratory tract infection and even acute respiratory distress syndrome 1-4. 
Even though COVID-19 in China has been temporarily contained through proactive 
public health interventions including early detection and quarantine, it has rapidly 
spread to cause a pandemic around the world. Up to 9 June, 2020, the global number 
of laboratory-confirmed cases had been more than 7.0 million, highlighting that 
COVID-19 poses a substantial threat to the international health.  
Characterizing the infectivity of SARS-CoV-2 is important for disease control and 
prevention. The duration of viral shedding, which has been recognized as a proxy 
measure of the infectious period for other respiratory viruses5,6, is a current 
consideration with SARS-CoV-2. Hence, it is of urgent need to elucidate the viral 
shedding duration among patients with COVID-19 to optimize public health 
management policy.  
COVID-19 is an infectious disease that transmitted mainly through respiratory tract. 
Therefore, consecutive detection of SARS-CoV-2 RNA from respiratory tract 
specimens using real-time reverse transcription–polymerase chain reaction (rRT-PCR) 
with approximate sensitivity of 70% and specificity of 95%7, is crucial for defining 
virus shedding duration and may impact clinical decisions on a patient's discharge 
from the hospital and whether isolation and surveillance is required depending on 
infection control recommendations in a particular country. Nasopharyngeal swab 
(NPS) has been widely used for diagnosis and dynamic observation of COVID-19 
patients on account of its ease of acquisition. Two consecutive negative detections of 
SARS-CoV-2 RNA in NPS specimens have been recognized as criterion for discharge 
from hospital or release from quarantine8-11. Nevertheless, one limitation of NPS is 
the possibility of false negative results, raising the concern that persistence of viral 
shedding might be present in lower respiratory tract12. 
Sputum has been reported to be more sensitive than NPS in SARS-CoV-2 RNA 
detection since SARS-CoV-2 mainly bind with ACE2 receptor of lower respiratory 
tract13-15. However, the use of sputum specimen in clinical practice is quite limited 
because only a proportion of patients with COVID-19 produce sputum spontaneously. 
Induced sputum is a convenient option to get lower respiratory tract samples and Han 
et.al. proposed in a case report that SARS-CoV-2 RNA could be detected more readily 
in sputum specimen than in upper respiratory tract specimen10. The risk of medical 
staff exposure to COVID-19 is lower with sputum induction than with 
bronchoalveolar lavage methods, although bronchoalveolar lavage fluid exhibited the 
higher positive rate compared with the nasal and pharyngeal swabs samples13,16. 
However, the SARS-CoV-2 detection yield and distinct virus shedding duration 
between sputum and NPS remained unclear. 
We conducted a prospective cohort study of 68 hospitalized patients with 
laboratory-confirmed COVID-19, by consecutively monitoring SARS-CoV-2 RNA 
detection from paired specimens of NPS and sputum aiming to identify viral shedding 
duration in upper and lower respiratory tract specimens respectively and to investigate 
possible factors associated with prolonged viral presence. 
 
Methods 
Data Collection
A cohort of 68 patients hospitalized (including intensive care unit [ICU] and non-ICU) 
in Wuhan Taikang Tongji Hospital and Huoshenshan Hospital were prospectively 
recruited from February 10 to March 20, 2020. They were all laboratory-confirmed 
COVID-19 patients according to the 7th version of ‘Pneumonia diagnosis and 
treatment for COVID-19 infection’ with specific clinical symptoms and radiological 
abnormalities and two sequential positive SARS-CoV-2 RNA tests or specific serum 
IgM and IgG antibodies of SARS-CoV-211. Demographic information, clinical indices, 
underlying diseases, treatment and outcome data were extracted from electronic 
medical records using a standardized data collection form. Study was approved by the 
Ethics Commission of Shanghai East Hospital, China and informed consent was 
obtained from participants. 
CURB-65 score was determined on the day of admission according to clinical criteria 
(confusion; urea >7 mmol/l; respiratory rate 30/min; either diastolic blood pressure 
60 mm Hg or systolic blood pressure <90 mm Hg; age 65 years) defined by the 
British Thoracic Society (BTS)17. 
Real-Time Reverse Transcription Polymerase Chain Reaction Assay for 
SARS-CoV-2 in Respiratory Samples 
Both nasopharyngeal swab and sputum specimens were collected every 1-2 days after 
admission for detection of the SARS-CoV-2 RNA using real-time reverse
transcription–polymerase chain reaction (rRT-PCR) until two sequential negative 
results were obtained. Briefly, induced sputum was obtained after inhalation of 10 mL 
of 3% hypertonic saline through a mask with oxygen at a flow rate of 6L/min for 20 
mins, if patients did not have sputum; tracheal aspirates sputum was collected through 
aspiration with a sterile catheter if patients were intubated. The SARS-CoV-2 
rRT-PCR assay was developed by Master Biotechnology (China) with primers and 
probes targeting the N and Orf1b genes of SARS-COV-2 and applied in the laboratory 
of Taikang Tongji Hospital and Huoshenshan Hospital. Respiratory specimens with 
cycle threshold (Ct) values of <37 were considered positive for SARS-CoV-2, and 
those with Ct values of 37.0 underwent repeat testing. Upon repeated testing, 
respiratory specimens with Ct values of <40 were considered positive for 
SARS-CoV-2, and those with Ct values of 40 or with undetectable results were 
considered negative. We defined the interval between symptom onset and the date of 
the first SARS-CoV-2 RNA negative result for respiratory samples including both 
nasopharyngeal swab and sputum specimens as the shedding duration. 
Antibody Detection 
Serum samples were detected for IgM/IgG antibodies against SARS-CoV-2 using the 
colloidal gold immunochromatography antibody detection kit (Innovita Biological 
Technology Co., Ltd., China). Briefly, the serum samples were firstly incubated at 
56°C for 30 minutes to heat-inactivate viruses, and then added into the sample well of 
the testing plate. After addition of reaction buffer and incubation for 10-15 minutes at 
room temperature, testing result could be achieved and interpreted according to the 
instructions.  
Statistical Analysis   
The measurement data of normal distribution were presented as mean ± standard 
deviation (SD) and compared by t test or variance analysis. While the measurement 
data of non-normal distribution were expressed by median (M) and upper and lower 
quartile spacing (IQN) and compared by Wilcoxon or Kruskal-Wallis Rank Sum Test. 
The categoric variables were presented as numbers and percentages and were 
compared by chi-square or Fisher exact test. The analyses of risk factors associated 
with detecting SARS-CoV-2 RNA in NPS or sputum or both were conducted using 
one-way ANOVA or the chi-square test. To identify risk factors associated with the 
duration of SARS-CoV-2 RNA shedding, we used a Cox proportional hazards model 
that adjusted for baseline covariates. Outcome was defined as time interval from 
symptom onset to SARS-CoV-2 RNA negativity in both NPS and sputum specimens. 
For this analysis, we censored patients if they never cleared SARS-CoV-2 RNA or, if 
they were discharged alive or dead before they had cleared SARS-CoV-2 RNA. 
Potential variables for analysis of prolonged duration of SARS-CoV-2 RNA shedding 
were as follows: sex, age, comorbidities, lymphocyte counts, and treatment with 
steroids. A hazard ratio (HR) of >1 indicated prolonged viral RNA shedding. In 
multivariable-adjusted Cox regression models, HR was further adjusted for covariates 
including age and sex. We performed Kaplan-Meier survival analysis to estimate the 
cumulative SARS-CoV-2 RNA-negativity rate among respiratory specimens and the 
stratified log-rank test to compare the difference of virus clearance between patients 
with age <65 years and 65 years. Statistical analyses were performed using STATA 
15 and two-sided p value < 0.05 was considered statistically significant. 
 
Results  
Demographic and clinical characteristics 
Overall, a total of 68 patients with COVID-19 who underwent consecutive 
SARS-CoV-2 RNA detection from NPS and sputum specimens were included: 36 
(52.9%) were men and 32 were (47.1%) women. The demographic and clinical 
characteristics of the patients are shown in Table 1. The median age of the patients 
was 67-year-old (interquartile range [IQR], 57 to 72). Fever was most commonly 
presented in 73.8% of the patients on admission (medium Tmax, °C [IQR], 38.5 
[38.0-39.0]) followed by cough (45.6%). Dyspnea (33.8%) and fatigue (32.4%) were 
also frequently observed and diarrhea (10.3%) was less common. The median 
duration of fever, cough and diarrhea was 11.0 days (IQR 8.0-13.0), 20.0 days 
(11.0-26.0), and 4.0 days (2.0-5.0), respectively. Comorbidities were present in 39 
(57.4%) patients, with chronic lung disease (17.6%) and diabetes mellitus (DM) 
(17.6%) being the most common underlying diseases, followed by cardiac disease 
(13.2%). Upon admission, 43 patients (63.2%) were diagnosed with COVID-19 based 
on positive NPS, while 25 patients (36.8%) based on positive serum IgM/IgG 
antibodies against SARS-CoV-2. During the hospitalization, the overall positive rate 
of serological test for IgM and IgG against SARS-CoV-2 were 76.5% (n=52) and 83.8% 
(n=57), respectively. As for treatment, 30 patients (44.2%) required mechanical 
ventilation. Among them, 5 were intubated and the rest 25 received noninvasive 
positive-pressure ventilation (NPPV). High-flow nasal cannula (HFNC) and 
conventional oxygen support were used in 21 (30.9 %) and 18 (26.5%) patients 
respectively. Upon admission, the severity of patients was evaluated by CURB-65: 30 
patients (44.1%) had score 1, 36 patients (52.9%) had score 2, and 2 patients reached 
score 3. Meanwhile, the overall mortality of all patients was 4.4%. 
Distinct yields of SARS-CoV-2 RNA detection in nasopharyngeal swab and sputum 
specimens. 
As shown in Figure 1, of all 68 patients with confirmed COVID-19, 72.1% (n=49) 
were identified with initial or follow-up positive NPS samples; 20.6% (n=14) patients 
with initial and follow-up negative NPS samples paired with follow-up positive 
sputum specimens; 7.4% (n=5) were diagnosed by serum IgM and IgG antibody assay 
while both NPS and sputum specimen remained negative during the hospitalization.  
Meanwhile, 16 patients were detected with SARS-CoV-2 RNA both in NPS and 
sputum specimens, among whom further analysis was carried out to characterize the 
time interval between the last time of NPS positive and the first time of sputum 
positive. As shown in Figure 2, 9 patients had positive testing for SARS-CoV-2 RNA 
in the sputum after NPS turned negative; 6 patients had positive sputum before NPS 
turned negative; 1 patient had positive sputum on the day when NPS turned negative. 
The time interval ranged from 6 days before to 16 days after the NPS turned negative.  
Factors associated with viral RNA detection yields of nasopharyngeal swab and 
sputum specimens 
We then explored the possible factors associated with the yields of NPS and sputum in 
detecting SARS-CoV-2 RNA respectively. The results showed chronic lung disease 
(CLD) and systemic steroids use were associated with SARS-CoV-2 RNA detection 
from sputum and diabetes mellitus was associated with viral RNA detection from 
NPS or sputum specimens. We futher performed a sensitivity analysis in patients 
without CLD in order to take into consideration of the possible effect of CLD on the 
association of systemic steroids with detection of SARS-CoV-2 RNA. There still 
existed a statistical difference in positive sputum rate between the steoids use group 
and non-steroids use group (steroids use: 11/17; non-steroids use: 9/39; P=0.003), 
which was consistent with the previous results. Besides, chronic lung disease was 
associated with both NPS and sputum positive for SARS-CoV-2 RNA detection. 
(Table 2). 
SARS-CoV-2 shedding duration and risk factors of prolonged viral presence 
The median duration of viral shedding from NPS and from sputum specimens was 19 
days (IQR 14-25 days) and 34 days (IQR 24-40 days), respectively (P<0.001), and by 
pooling together, the median duration of SARS-CoV-2 RNA shedding from either 
NPS or sputum specimens was 21 days (IQR, 16-31 days). Of 63 patients with 
rRT-PCR confirmed SARS-CoV-2 infection, only 4 patients (6.3%) had undetectable 
virus RNA within 8 days, 18 patients (28.6%) tested negative within 14 days, and 41 
patients (65.1%) tested negative within 28 days after illness onset (Figure 3).  
We further explored SARS-CoV-2 shedding duration and potential risk factors. In a 
multivariable model, elderly age ( 65 years) was identified as an independent factor 
associated with the viral shedding time in hospitalized patients (Table 3). 
SARS-CoV-2 RNA clearance was significantly delayed in patients aged 65 years 
compared with those aged <65 years after onset of illness (HR, 1.71 [95%CI, 
1.12-2.93]; p<0.01; Figure 3B). 
Recurrent positive detections of viral RNA from nasopharyngeal swab specimens in 
2 cases 
We found 2 patients who had recurrent positive detection of SARS-CoV-2 RNA from 
NPS specimens (Figure 4) after serially negative tests. Case 1 is a 68-year-old woman 
with a history of diabetes mellitus for 20 years. After 9 consecutive negative NPS 
tests, SARS-CoV-2 RNA was detected again in NPS at day 29 after illness onset 
while the SP were tested positive serially for 6 times from day 16 to day 29. Case 2 is 
a 55-year-old man with hypertension and cardiac disease. From day 9 to day 25 after 
illness onset, the patient had 11 consecutive negative NPS test and 7 consecutive 
positive SP tests, and then he had recurrent positive detection of virus RNA in NPS at 
day 25. These two cases continued to receive isolation and surveillance in hospital 
until NPS test turned negative. When these two cases converted to NPS positive, they 
remained clinically stable without recurrence of symptoms and substantial changes in 
laboratory examinations.  
 
Discussion 
In the present study, we have found the median duration of SARS-CoV-2 shedding 
from either NPS or sputum specimens was 21 days and the median duration of viral 
shedding from sputum was significantly longer than from NPS. Age was identified as 
an independent risk factor of prolonged viral shedding time. Meanwhile, a 
combination of NPS and sputum specimens for detecting viral RNA could improve 
the diagnostic sensitivity. Chronic lung disease and steroids use are associated with 
the detection of virus RNA from NPS, and DM is associated with the detection of 
virus RNA from both NPS and sputum specimens. In addition, it was noteworthy that 
in 9 of 16 hospitalized patients where SARS-CoV-2 RNA was detected both in NPS 
and sputum specimens, virus RNA could be detected in sputum specimen after the 
NPS specimen turned negative.  
Since coronavirus RNA detection is more sensitive than virus isolation by culture, 
most studies have used viral RNA tests as a potential marker to assess the potential 
transmission risk and to inform decisions regarding patients’ isolation. For SARS-and 
MERS-COV, the duration of viral RNA detection in respiratory specimens was about 
3-4 weeks after illness onset18-20. Recently, Cao et.al reported that SARS-COV-2 RNA 
persisted for a median of 20 days in survivors and that is consistent with the findings 
from our present study21. Additionally, we have found that age was an independent 
factor associated with prolonged SARS-COV-2 RNA shedding. Previously, it has 
been suggested that increased age was associated with mortality in SARS and MERS 
and may lead to death in COVID-19 patients22,23. One possible reason for this is the 
age-dependent dysfunction of lymphocyte and the overproduction of type 2 
cytokines24. This could further result on slower viral clearance and prolonged 
shedding time21.  
According to the Chinese guideline for COVD-1911, the criteria for discharge were 
absence of fever for at least 3 days, substantial improvement in both lungs in chest CT, 
clinical remission of respiratory symptoms, and two throat-swab samples negative for 
SARS-CoV-2 RNA obtained at least 24 h apart25. However, there is growing evidence 
showing that a certain amount of discharged patients have tested positive during 
follow-up9. In the present study, we describe two patients in detail who had a 
recurrence of detection of SARS CoV-2 virus RNA from NPS after previously 
converting to negative testing. The possible reasons for the relapse are multifold. First, 
COVID-19 is a novel coronaviral infectious disease, so the clinical features and 
course has not been fully understood. The pathogen of the disease is an RNA 
beta-coronavirus named SARS-COV-2 and mutation may occur during transmission 
which could lead to ineffective antibodies produced by the recovered patients. If the 
discharged patient is re-infected by the mutated virus, the nucleic acid test may be 
positive again. Negative results may also occur if a patient still has very low levels of 
viral shedding, but their viral load is below the lower threshold of assay detection.  
In the present study, we found that viral RNA could be detected in sputum specimen 
after the NPS specimen turned negative, which was consistent with previous report 
describing 22 patients with COVID-19 who had positive rRT-PCR results for SARS–
CoV-2 in the sputum or feces after negative conversion of pharyngeal swabs26. We 
also found that the duration of viral shedding in sputum specimens was longer than 
that in NPS. These findings may impact a test based clearance discharge criteria given 
patients with COVID-19 may shed virus longer in their respiratory tracts, with 
potential implication for prolonged transmission risk. Additionally, although not 
routinely recommended for initial diagnostic testing for SARS-CoV-227, induced 
sputum should be considered as an alternative for testing SARS–CoV-2 RNA when 
individuals are highly suspected of COVID-19 but nasopharyngeal or oropharyngeal 
consecutively negative.  
There are still several limitations of the present study. First, the interpretation of our 
findings might be limited by its small sample size. Second, NPS specimens were 
obtained by different clinicians and this could have an impact on its detecting 
sensitivity. Third, lymphocyte subtypes and serum IgM/IgG antibody titers test were 
not performed. It was therefore not possible to determine the relationship between 
antiviral response and prolonged SARS-CoV-2 shedding. At last, another limitation is 
that we detected virus by rRT-PCR instead of by virus isolation by culture. It is 
becoming more widely accepted that prolonged viral shedding may not indicate 
infectivity, because rRT-PCR does not distinguish between infectious virus and 
non-infectious nucleic acid.28 In spite of this, relative cautious management strategies 
are still warranted for optimal transmission prevention, especially among vulnerable 
populations and healthcare staffs. Further studies are needed to determine whether 
individuals with prolonged positive NPS or sputum are infectious or not.   
 
Interpretation 
In patients hospitalized with COVID-19, the median duration of viral shedding from 
sputum specimens was significantly longer than from NPS. Elderly age was 
independently associated with prolonged SARS-CoV-2 shedding in the respiratory 
specimens. Viral RNA could be detected in sputum specimen after the nasopharyngeal 
swabs became negative in some patients. These findings may impact a test based 
clearance discharge criteria given patients with COVID-19 may shed virus longer in 
lower respiratory tracts, with potential implication for prolonged transmission risk. In 
addition, more attention should be given to elderly patients who might have prolonged 
viral shedding period. Besides, more studies are needed to determine whether 
prolonged viral shedding indicates infectivity of patients.  
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Table 1. Demographic and Clinical Characteristics of 68 COVID-19 Patients. 
Demographic and clinical characteristics Patients (n=68)  
Age  
Yrs (M, IQR)  67 (57-72) 
65 years — no. (%) 40 (58.8) 
Male — no. (%) 36 (52.9) 
Underlying diseases — no. (%)  
  Chronic lung disease 12 (17.6) 
  Diabetes mellitus 12 (17.6) 
  Cardiac disease 9 (13.2) 
  Malignant tumor 3 (4.4) 
Clinical features — no. (%)  
Fever 50 (73.5) 
  T, °C (M, IQR) 38.5 (38-39) 
Cough 31 (45.6) 
  Dyspnea 23 (33.8) 
  Fatigue 22 (32.4) 
  Diarrhea 7 (10.3) 
Patients diagnosed with COVID-19 at 
admission— no. (%) 
 
by NPS (+) 43 (63.2) 
by IgM/IgG (+) 25 (36.8) 
IgM/IgG against SARS-CoV-2 during 
hospitalization— no. (%) 
 
  IgM positive 52 (76.5) 
  IgG positive 57 (83.8) 
Respiratory support— no. (%)  
  NPPV 25 (36.8) 
  HFNC 21 (30.9) 
Conventional oxygen therapy 18 (26.5) 
  Intubation 5 (7.4) 
CURB-65— no. (%)  
  1 30 (44.1) 
  2 36 (52.9) 
  3 2 (2.9) 
Duration of different symptoms in survivors, days 
(M, IQR) 
 
Fever 11.0 (8.0-13.0) 
Cough 20.0 (11.0-26.0) 
Diarrhea 4.0 (2.0-5.0) 
Mortality—no.(%) 3 (4.4) 
M, IQR: Median, Inter Quartile Range. NPPV: noninvasive positive-pressure 
ventilation. NPS, nasopharyngeal swab. HFNC: high-flow nasal cannula oxygen 
therapy. SP, sputum. Yrs (M, IQR): Years, (Median, Inter Quartile Range). 
 
 
Table 2. Factors associated with SARS-CoV-2 RNA detection yields in nasopharyngeal swab and sputum specimens during the 
hospitalization.   
Characteristics NPS(+) NPS(-) P value SPb(+) SP(-) P value NPS(+)&SP(+) Others P value 
 (N=49) (N=19)  (N=30) (N=38)  (N=16) (N=52)  
Chronic lung disease 8 4 0.646 10 2 0.003 6 6 0.017 
Diabetes mellitus 5 7 0.010 9 3 0.018 3 9 0.895 
Fever 35 15 0.398 25 25 0.103 14 36 0.147 
Cough 23 7 0.452 13 17 0.908 7 23 0.973 
Fatigue 16 6 0.932 9 13 0.712 6 16 0.615 
Diarrhea 6 1 0.395 4 3 0.464 3 4 0.203 
Steroids 12 8 0.153 13 7 0.025 7 13 0.150 
Lymphocyte numbers 0.88±0.47 1.13±0.75 0.721 0.99±0. 47 1.14±0.89 0.135 1.00±0.20 1.00±0.06 0.517 
 NPS: nasopharyngeal swab. SP: sputum specimen. 
Table 3. Multivariable analyses of risk factors associated with duration of 
SARS-CoV-2 RNA detection in hospitalized patients. 
Characteristics Unadjusted HR 
(95% CI) 
P value Adjusted HR* 
(95% CI) 
P value 
Age 65yrs 1.66 (0.99- 2.82) 0.06 1.71 (1.01-2.93) 0.04 
Sex, male 1.04 (0.63-1.73) 0.867 1.21 (0.69-2.13) 0.50 
Diabetes mellitus 0.57 (0.30-1.08) 0.18 0.64 (0.31-1.29) 0.21 
Chronic lung diseases 0.72 (0.38-1.36) 0.30 0.88 (0.40-1.97) 0.76 
Lymphocyte counts 1.01 (.083-1.23) 0.91 0.98 (0.78-1.21) 0.83 
Systemic steroids 0.74 (0.41-1.32) 0.30 1.08 (0.51-2.24) 0.84 
Cardiac diseases 0.59 (0.29-1.20) 0.12 1.00 (0.45-2.27) 0.99 
Hypertension 0.61 (0.34-1.10) 0.09 0.55 (0.26-1.16) 0.76 
Malignant tumor 0.23 (0.30-1.70) 0.07 0.15 (0.16-1.49) 0.11 
HR (95%CI): hazard ratio (95% confidence interval). Yrs: years 
* Adjusted for age and sex. 
Figure Legends  
Figure 1. Detection of SARS-CoV-2 RNA in nasopharyngeal swab and sputum 
specimen from COVID-19 patients during the hospitalization.  
NPS (+): nasopharyngeal swab specimen positive. NPS (-): nasopharyngeal swab 
specimen negative. SP (+): sputum specimen positive. SP (-): sputum specimen 
negative. 
 
Figure 2. Results of SARS-CoV-2 RNA detection in 16 patients with both NPS 
and SP samples positive, by timing of first positive testing for SARS-CoV-2 RNA. 
Day 0 is the day of first positive testing for SARS-CoV-2 RNA in each patient. 
NPS: nasopharyngeal swab. SP: sputum. 
 
 
Figure 3. Cumulative proportion of patients who had detectable SARS-CoV-2 
RNA by days after onset of illness. (A) From both NPS and SP specimens; (B) 
from NPS and SP separately; (C) with age <65 years versus 65 years, 
respectively. 
NPS: nasopharyngeal swab. SP: sputum. 
 
Figure 4. Illustrated information about 2 cases that patients had recurrent 
positive detection of SARS-COV-2 RNA from nasopharyngeal swab. 
NPS (+): nasopharyngeal swab specimen positive. NPS (-): nasopharyngeal swab 
specimen negative. SP (+): sputum specimen positive. 
 
 
 
 
 




